ES102

DRUG3 trials

Sponsors

Elpiscience Biopharma, Ltd., Elpiscience (Suzhou) Biopharma, Ltd.

Conditions

Malignant TumorNeoplasmsNon-Small Cell Lung CancerSolid TumorSolid Tumors

Phase 1

A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors

CompletedNCT04730843

Elpiscience Biopharma, Ltd.Malignant Tumor, Neoplasms, Solid Tumors

Start: 2021-04-01End: 2024-03-01Updated: 2025-06-23

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

CompletedNCT04991506

Elpiscience Biopharma, Ltd.Malignant Tumor, Neoplasms, Solid Tumor

Start: 2021-10-15End: 2024-05-17Updated: 2025-06-23

Phase 2

A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

RecruitingNCT06623136

Elpiscience (Suzhou) Biopharma, Ltd.Non-Small Cell Lung Cancer

Start: 2025-04-30End: 2027-12-31Target: 40Updated: 2025-09-26